Endothelial Vehicles as a Novel Anti-Angiogenic Gene Therapy in Cancer of Prostate
Abstract
Tumor angiogenesis is the common pathophysiological factor of both primary tumors and distant metastases. Therefore, the ablation of the antiogenesis may have a key role to stop tumor progression. In this regard, we and others have shown that, when given systemically, normal endothelial progenitors (Eps) circulate and localize into areas of active angiogenesis. In the proposal, we will evaluate the employment of these EPs as cellular vehicles for gene delivery into primary and metastatic carcinoma of the prostate. To this end, we will apply EPs genetically modified ex vivo with a toxin gene for cell- mediated molecular chemotherapy. Thus, if localization occurs in the areas of tumor angiogenesis as proposed, expression of the toxin gene inside he EPs could induce death in these toxin-expressing cells and their neighbors, thus abrogating angiogenesis, and therefore potentially inducing regression of the tumor thereafter by vascular deprivation.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2003
- Accession Number
- ADA419490
Entities
People
- Waleed Arafat
Organizations
- University of Alabama